SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : biotech firesales
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: Julius Wong7/15/2016 8:35:17 AM
   of 3661
 
Patient deaths in Ziopharm's IL-12 brain tumor trial sink shares, down 22% premarket
  • Ziopharm (NASDAQ: ZIOP) slumps 22% premarket on robust volume in response to its disclosure in a presentation (slide 19) yesterday that a patient in its IL-12 glioblastoma clinical trial died from an intracranial hemorrhage 15 days after being treated.
  • A second patient also died, at 3.9 months follow-up. A third death was previously reported due to progressive disease (6.4 months). The two new deaths are not believed to be related to IL-12 therapy.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News